SOUTH SAN FRANCISCO, Calif., Aug. 28, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that it has named Daniel G. Welch to its Board of Directors. Mr. Welch currently serves as Chairman, Chief Executive Officer and President of InterMune, Inc., a public biotechnology company based in Brisbane, California.
"We expect that Dan's breadth of experience successfully leading commercial stage pharmaceutical and biotechnology companies will complement the expertise resident in our board and management team. As we approach our fourth quarter PDUFA date, we are actively planning for the potential launch of Ravicti™, and look forward to Dan's contributions in this critical effort." said Donald J. Santel, Chief Executive Officer of Hyperion.
Mr. Welch has more than 30 years of experience in the biotechnology and pharmaceutical industries. Prior to InterMune, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., from 2002 to 2003. From 2000 to 2002, Welch served as President of the pharmaceutical division at Elan, plc., and from 1987 to 2000, Mr. Welch served in various senior management roles at Sanofi-Synthelabo (now Sanofi-Aventis) and its predecessor companies Sanofi and Sterling Winthrop. There, while serving as Vice President of Worldwide Marketing, he led the successful worldwide launches of several leading products, notably Plavix®, Avapro®, Eloxatin®. From 1980 to 1987, Welch was with American Critical Care, a division of American Hospital Supply. He currently serves on the board of directors for Seattle Genetics, a biotechnology company and also serves on the board of directors for a privately held company. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina.About Hyperion Therapeutics Hyperion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion Therapeutics is developing Ravicti™ (glycerol phenylbutyrate) for two orphan indications: urea cycle disorders and hepatic encephalopathy.